Related Experiment Videos
Interindividual human variation in cisplatinum sensitivity, predictable in an in vitro assay?
Mutation Research
|January 1, 1987
Summary
Measuring cisplatinum-DNA crosslinks in white blood cells can predict patient response to chemotherapy. This method helps tailor cisplatinum treatment, potentially improving outcomes and reducing side effects.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cisplatinum (cis-diamminedichloroplatinum(II)) is a potent anticancer drug.
- Its efficacy relies on forming cisplatinum-DNA crosslinks.
- Understanding these crosslinks is crucial for optimizing cancer therapy.
Purpose of the Study:
- To measure cisplatinum-DNA intrastrand crosslinks in patients' white blood cells.
- To assess the correlation between in vitro and in vivo cisplatinum exposure.
- To determine if in vitro measurements can predict treatment response and toxicity.
Main Methods:
- Quantification of cisplatinum-DNA intrastrand crosslinks in nucleated white blood cells.
- In vitro analysis of pretreatment blood samples exposed to cisplatinum.
- In vivo analysis of cells from patients immediately post-cisplatinum administration.
Main Results:
- Significant interpatient variability in cisplatinum-DNA crosslink formation was observed.
- A strong linear correlation (cc = 0.91) was found between in vitro and in vivo data.
- In vitro crosslink measurements accurately reflected in vivo exposure.
Conclusions:
- In vitro assessment of cisplatinum-DNA crosslinks is a reliable predictor of in vivo effects.
- This method holds potential for personalized medicine in cisplatinum chemotherapy.
- Predictive measurements may guide treatment decisions to enhance efficacy and minimize toxicity.